See more : Lavras Gold Corp. (LGC.V) Income Statement Analysis – Financial Results
Complete financial analysis of NextCure, Inc. (NXTC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of NextCure, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- African Energy Metals Inc. (NDENF) Income Statement Analysis – Financial Results
- VEEFIN SOLUTIONS LIMITED (VEEFIN.BO) Income Statement Analysis – Financial Results
- WeCommerce Holdings Ltd. (WE.V) Income Statement Analysis – Financial Results
- Télévision Française 1 Société anonyme (TFI.PA) Income Statement Analysis – Financial Results
- Fastighetsbolaget Emilshus AB (publ) (EMIL-PREF.ST) Income Statement Analysis – Financial Results
NextCure, Inc. (NXTC)
About NextCure, Inc.
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors. The company is also developing NC410, which is in Phase I for novel immunomedicine designed to block immune suppression mediated by an immune modulator called Leukocyte-Associated Immunoglobulin-like Receptor 1; NC762, an immunomedicine targeting a molecule called human B7 homolog 4 protein, or B7-H4; and NC525, a novel LAIR-1 antibody which is in Preclinical trails that targets acute myeloid leukemia, blast cells, and leukemic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. The company has a license agreement with Yale University. NextCure, Inc. was incorporated in 2015 and is headquartered in Beltsville, Maryland.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 22.38M | 6.35M | 0.00 | 0.00 |
| Cost of Revenue | 3.68M | 4.48M | 4.30M | 46.55K | 34.22K | 1.68M | 582.00K |
| Gross Profit | -3.68M | -4.48M | -4.30M | 22.33M | 6.31M | -1.68M | -582.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 99.79% | 99.46% | 0.00% | 0.00% |
| Research & Development | 47.93M | 54.20M | 50.19M | 46.55M | 34.22M | 19.79M | 12.95M |
| General & Administrative | 19.71M | 21.71M | 20.57M | 17.05M | 9.61M | 3.41M | 2.60M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 19.71M | 21.71M | 20.57M | 17.05M | 9.61M | 3.41M | 2.60M |
| Other Expenses | 0.00 | 1.18M | 1.38M | 4.62M | 3.75M | 397.00K | 80.00K |
| Operating Expenses | 67.64M | 75.91M | 70.77M | 63.60M | 43.83M | 23.20M | 15.55M |
| Cost & Expenses | 67.64M | 75.91M | 70.77M | 63.60M | 43.83M | 23.20M | 15.55M |
| Interest Income | 0.00 | 1.17M | 1.32K | 4.55K | 3.75K | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 77.00K | 183.00K | 209.00K | 0.00 | 0.00 |
| Depreciation & Amortization | 3.68M | 4.48M | 4.30M | 3.41M | 2.69M | 1.68M | 582.00K |
| EBITDA | -59.04M | -70.25M | -65.01M | -37.81M | -34.79M | -21.10M | -14.97M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | -184.22% | -548.20% | 0.00% | 0.00% |
| Operating Income | -67.64M | -75.91M | -70.77M | -41.23M | -37.48M | -23.20M | -15.55M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | -184.22% | -590.55% | 0.00% | 0.00% |
| Total Other Income/Expenses | 4.91M | 1.18M | 1.38M | 4.62M | 3.75M | 397.00K | 80.00K |
| Income Before Tax | -62.72M | -74.73M | -69.39M | -36.60M | -33.74M | -22.80M | -15.47M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | -163.57% | -531.54% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -5.30M | 6.96M | -3.41M | 2.52M | 397.00K | 0.00 |
| Net Income | -62.72M | -69.43M | -69.39M | -33.19M | -33.74M | -22.80M | -15.47M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | -148.32% | -531.54% | 0.00% | 0.00% |
| EPS | -2.25 | -2.50 | -2.51 | -1.21 | -2.15 | -2.27 | -1.54 |
| EPS Diluted | -2.25 | -2.50 | -2.51 | -1.21 | -2.15 | -2.27 | -1.54 |
| Weighted Avg Shares Out | 27.84M | 27.74M | 27.62M | 27.53M | 15.70M | 10.04M | 10.04M |
| Weighted Avg Shares Out (Dil) | 27.84M | 27.74M | 27.62M | 27.53M | 15.70M | 10.04M | 10.04M |
NextCure to Participate in the 36th Annual Piper Sandler Healthcare Conference
BELTSVILLE, Md., Nov. 26, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced that it will participate in a fireside chat at...
Preclinical Data Demonstrates Anti-Siglec-15 Treatment Enhanced Generation of Quality Bone with Better Mechanical Properties in Mice with Moderate-to-Severe Osteogenesis Imperfecta
BELTSVILLE, Md., Nov. 19, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced the presentation of preclinical data demonstrating that treatment with NC605,...
NextCure Provides Business Update and Reports Third Quarter 2024 Financial Results
BELTSVILLE, Md., Nov. 07, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in-class therapies to treat cancer, today provided a business update and reported third-quarter 2024 financial results.
NextCure Reports Preclinical Data for LNCB74 and Additional Clinical Biomarker Data for NC410 Combo at Society for Immunotherapy of Cancer Annual Meeting
BELTSVILLE, Md., Nov. 05, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today reports pre-clinical data from LNCB74, a B7-H4-targeting antibody-drug conjugate (ADC) being...
NextCure to Give Two Presentations at Society for Immunotherapy of Cancer Annual Meeting
BELTSVILLE, Md., Oct. 04, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced two presentations at the Society for Immunotherapy of Cancer (SITC)...
NextCure Presented Results of the Phase 1b Study of NC410 in Combination with Pembrolizumab at ESMO 2024
BELTSVILLE, Md., Sept. 16, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced that clinical data from the Phase 1b portion of...
NextCure to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
BELTSVILLE, Md., June 20, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies, today announced that it will present and host institutional investor meetings at the H.C....
NextCure Presents Phase 1b Data on NC410 and Pembrolizumab Combination at ASCO 2024
BELTSVILLE, Md., May 30, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced that clinical data from the Phase 1b portion of a...
NextCure Provides Business Update and Reports First Quarter 2024 Financial Results
BELTSVILLE, Md., May 02, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in-class therapies to treat cancer, today provided a business update and reported its first-quarter 2024 financial...
NextCure to Present Phase 1b Data of NC410 in Combination with Pembrolizumab at ASCO 2024
BELTSVILLE, Md., April 24, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced that clinical trial investigator Eric S.
Source: https://incomestatements.info
Category: Stock Reports